Although increases in weight are common among patients with HIV infection after initiating antiretroviral therapy (ART) with second generation integrase strand transfer inhibitor (INSTI)- or tenofovir alafenamide (TAF)-based regimens, significant weight gain in the first year of therapy is not associated with type of ART regimen or continued weight gain over time, according to study findings published in Open Forum Infectious Diseases.
Read the full news story at Infectious Disease Advisor.
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.